BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu LZ, Zhou XD, Qian G, Shi X, Fang J, Jiang BH. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer Res. 2007;67:6325-6332. [PMID: 17616691 DOI: 10.1158/0008-5472.can-06-4261] [Cited by in Crossref: 141] [Cited by in F6Publishing: 87] [Article Influence: 9.4] [Reference Citation Analysis]
Number Citing Articles
1 Thomas A, Reetz S, Stenzel P, Tagscherer K, Roth W, Schindeldecker M, Michaelis M, Rothweiler F, Cinatl J Jr, Cinatl J, Dotzauer R, Vakhrusheva O, Albersen M, Macher-Goeppinger S, Haferkamp A, Juengel E, Neisius A, Tsaur I. Assessment of PI3K/mTOR/AKT Pathway Elements to Serve as Biomarkers and Therapeutic Targets in Penile Cancer. Cancers (Basel) 2021;13:2323. [PMID: 34066040 DOI: 10.3390/cancers13102323] [Reference Citation Analysis]
2 Dhar R, Persaud SD, Mireles JR, Basu A. Proteolytic cleavage of p70 ribosomal S6 kinase by caspase-3 during DNA damage-induced apoptosis. Biochemistry 2009;48:1474-80. [PMID: 19191576 DOI: 10.1021/bi801840s] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
3 López-Cortés A, Leone PE, Freire-Paspuel B, Arcos-Villacís N, Guevara-Ramírez P, Rosales F, Paz-Y-Miño C. Mutational Analysis of Oncogenic AKT1 Gene Associated with Breast Cancer Risk in the High Altitude Ecuadorian Mestizo Population. Biomed Res Int 2018;2018:7463832. [PMID: 30065942 DOI: 10.1155/2018/7463832] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
4 Yip HYK, Papa A. Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments. Cells 2021;10:659. [PMID: 33809714 DOI: 10.3390/cells10030659] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Wu H, Zhou J, Mei S, Wu D, Mu Z, Chen B, Xie Y, Ye Y, Liu J. Circulating exosomal microRNA-96 promotes cell proliferation, migration and drug resistance by targeting LMO7. J Cell Mol Med 2017;21:1228-36. [PMID: 28026121 DOI: 10.1111/jcmm.13056] [Cited by in Crossref: 57] [Cited by in F6Publishing: 68] [Article Influence: 9.5] [Reference Citation Analysis]
6 Wang Y, Chen L, Huang G, He D, He J, Xu W, Zou C, Zong F, Li Y, Chen B, Wu S, Zhao W, Wu J. Klotho sensitizes human lung cancer cell line to cisplatin via PI3k/Akt pathway. PLoS One 2013;8:e57391. [PMID: 23437382 DOI: 10.1371/journal.pone.0057391] [Cited by in Crossref: 36] [Cited by in F6Publishing: 41] [Article Influence: 4.0] [Reference Citation Analysis]
7 Gálvez-Peralta M, Flatten KS, Loegering DA, Peterson KL, Schneider PA, Erlichman C, Kaufmann SH. Context-dependent antagonism between Akt inhibitors and topoisomerase poisons. Mol Pharmacol. 2014;85:723-734. [PMID: 24569089 DOI: 10.1124/mol.113.088674] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
8 Basu A, Krishnamurthy S. Cellular responses to Cisplatin-induced DNA damage. J Nucleic Acids. 2010;2010. [PMID: 20811617 DOI: 10.4061/2010/201367] [Cited by in Crossref: 177] [Cited by in F6Publishing: 207] [Article Influence: 14.8] [Reference Citation Analysis]
9 Ma BB, Lui VW, Hui EP, Lau CP, Ho K, Ng MH, Cheng SH, Tsao SW, Chan AT. The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines. Invest New Drugs 2010;28:413-20. [PMID: 19471857 DOI: 10.1007/s10637-009-9269-x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 3.2] [Reference Citation Analysis]
10 Huang Y, Sen T, Nagpal J, Upadhyay S, Trink B, Ratovitski E, Sidransky D. ATM kinase is a master switch for the Delta Np63 alpha phosphorylation/degradation in human head and neck squamous cell carcinoma cells upon DNA damage. Cell Cycle 2008;7:2846-55. [PMID: 18769144 DOI: 10.4161/cc.7.18.6627] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 2.6] [Reference Citation Analysis]
11 Do H, Solomon B, Mitchell PL, Fox SB, Dobrovic A. Detection of the transforming AKT1 mutation E17K in non-small cell lung cancer by high resolution melting. BMC Res Notes 2008;1:14. [PMID: 18611285 DOI: 10.1186/1756-0500-1-14] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
12 Ryu JS, Lim JH, Kim HJ, Kim MJ, Park MH, Kim JS. Survival prediction of tuberous sclerosis complex gene variant in patients with advanced non-small-cell lung cancer treated with platinum doublet. Biosci Rep 2019;39:BSR20181426. [PMID: 30842342 DOI: 10.1042/BSR20181426] [Reference Citation Analysis]
13 Jiffar T, Yilmaz T, Lee J, Hanna E, El-Naggar A, Yu D, Myers JN, Kupferman ME. KiSS1 mediates platinum sensitivity and metastasis suppression in head and neck squamous cell carcinoma. Oncogene 2011;30:3163-73. [PMID: 21383688 DOI: 10.1038/onc.2011.39] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
14 Ortolan E, Giacomino A, Martinetto F, Morone S, Lo Buono N, Ferrero E, Scagliotti G, Novello S, Orecchia S, Ruffini E, Rapa I, Righi L, Volante M, Funaro A. CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome. Oncotarget 2014;5:6191-205. [PMID: 25026285 DOI: 10.18632/oncotarget.2186] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
15 Jia J, Wang Z, Cai J, Zhang Y. PMS2 expression in epithelial ovarian cancer is posttranslationally regulated by Akt and essential for platinum-induced apoptosis. Tumour Biol 2016;37:3059-69. [PMID: 26423401 DOI: 10.1007/s13277-015-4143-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
16 Pu X, Hildebrandt MA, Lu C, Lin J, Stewart DJ, Ye Y, Gu J, Spitz MR, Wu X. PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy. Lung Cancer 2011;71:82-8. [PMID: 20447721 DOI: 10.1016/j.lungcan.2010.04.008] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 3.8] [Reference Citation Analysis]
17 Jiang W, Zhang W, Wu L, Liu L, Men Y, Wang J, Liang J, Hui Z, Zhou Z, Bi N, Wang L. MicroRNA-Related Polymorphisms in PI3K/Akt/mTOR Pathway Genes Are Predictive of Limited-Disease Small Cell Lung Cancer Treatment Outcomes. Biomed Res Int 2017;2017:6501385. [PMID: 28280736 DOI: 10.1155/2017/6501385] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
18 Jiang BH, Liu LZ. Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist Updat. 2008;11:63-76. [PMID: 18440854 DOI: 10.1016/j.drup.2008.03.001] [Cited by in Crossref: 153] [Cited by in F6Publishing: 158] [Article Influence: 10.9] [Reference Citation Analysis]
19 Leal P, Garcia P, Sandoval A, Buchegger K, Weber H, Tapia O, Roa JC. AKT/mTOR substrate P70S6K is frequently phosphorylated in gallbladder cancer tissue and cell lines. Onco Targets Ther 2013;6:1373-84. [PMID: 24124380 DOI: 10.2147/OTT.S46897] [Cited by in Crossref: 1] [Cited by in F6Publishing: 12] [Article Influence: 0.1] [Reference Citation Analysis]
20 Arnedos M, Bihan C, Delaloge S, Andre F. Triple-negative breast cancer: are we making headway at least? Ther Adv Med Oncol 2012;4:195-210. [PMID: 22754593 DOI: 10.1177/1758834012444711] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 5.2] [Reference Citation Analysis]
21 Huang BX, Newcomer K, Kevala K, Barnaeva E, Zheng W, Hu X, Patnaik S, Southall N, Marugan J, Ferrer M, Kim HY. Identification of 4-phenylquinolin-2(1H)-one as a specific allosteric inhibitor of Akt. Sci Rep 2017;7:11673. [PMID: 28916818 DOI: 10.1038/s41598-017-11870-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
22 Jeong M, Jeong MH, Kim JE, Cho S, Lee KJ, Park S, Sohn J, Park YG. TCTP protein degradation by targeting mTORC1 and signaling through S6K, Akt, and Plk1 sensitizes lung cancer cells to DNA-damaging drugs. Sci Rep 2021;11:20812. [PMID: 34675258 DOI: 10.1038/s41598-021-00247-0] [Reference Citation Analysis]
23 Han J, Zhao F, Zhang J, Zhu H, Ma H, Li X, Peng L, Sun J, Chen Z. miR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway. Int J Oncol 2016;48:1855-67. [PMID: 26936292 DOI: 10.3892/ijo.2016.3401] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 6.8] [Reference Citation Analysis]
24 Chao SY, Chiang JH, Huang AM, Chang WS. An integrative approach to identifying cancer chemoresistance-associated pathways. BMC Med Genomics 2011;4:23. [PMID: 21429228 DOI: 10.1186/1755-8794-4-23] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
25 Woolf N, Pearson BE, Bondzie PA, Meyer RD, Lavaei M, Belkina AC, Chitalia V, Rahimi N. Targeting tumor multicellular aggregation through IGPR-1 inhibits colon cancer growth and improves chemotherapy. Oncogenesis 2017;6:e378. [PMID: 28920928 DOI: 10.1038/oncsis.2017.77] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
26 Jiang X, Lei T, Zhang M. Expression and Functions of Formyl Peptide Receptor 1 in Drug-Resistant Bladder Cancer. Technol Cancer Res Treat 2018;17:1533034618769413. [PMID: 29665744 DOI: 10.1177/1533034618769413] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
27 Li W, Wang J, Chen QD, Qian X, Li Q, Yin Y, Shi ZM, Wang L, Lin J, Liu LZ, Jiang BH. Insulin promotes glucose consumption via regulation of miR-99a/mTOR/PKM2 pathway. PLoS One 2013;8:e64924. [PMID: 23762265 DOI: 10.1371/journal.pone.0064924] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
28 Kim DJ, Reddy K, Kim MO, Li Y, Nadas J, Cho YY, Kim JE, Shim JH, Song NR, Carper A, Lubet RA, Bode AM, Dong Z. (3-Chloroacetyl)-indole, a novel allosteric AKT inhibitor, suppresses colon cancer growth in vitro and in vivo. Cancer Prev Res (Phila) 2011;4:1842-51. [PMID: 21885813 DOI: 10.1158/1940-6207.CAPR-11-0158] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
29 Kang W, Zhang J, Huang T, Zhou Y, Wong CC, Chan RCK, Dong Y, Wu F, Zhang B, Wu WKK, Chan MWY, Cheng ASL, Yu J, Wong N, Lo KW, To KF. NOTCH3, a crucial target of miR-491-5p/miR-875-5p, promotes gastric carcinogenesis by upregulating PHLDB2 expression and activating Akt pathway. Oncogene 2021;40:1578-94. [PMID: 33452458 DOI: 10.1038/s41388-020-01579-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
30 Pouliot LM, Chen YC, Bai J, Guha R, Martin SE, Gottesman MM, Hall MD. Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family. Cancer Res 2012;72:5945-55. [PMID: 22942255 DOI: 10.1158/0008-5472.CAN-12-1400] [Cited by in Crossref: 71] [Cited by in F6Publishing: 48] [Article Influence: 7.1] [Reference Citation Analysis]
31 Feng F, Cheng P, Wang C, Wang Y, Wang W. Polyphyllin I and VII potentiate the chemosensitivity of A549/DDP cells to cisplatin by enhancing apoptosis, reversing EMT and suppressing the CIP2A/AKT/mTOR signaling axis. Oncol Lett 2019;18:5428-36. [PMID: 31612051 DOI: 10.3892/ol.2019.10895] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
32 Smith PA, Merritt D, Barr L, Thorley-Lawson DA. An orthotopic model of metastatic nasopharyngeal carcinoma and its application in elucidating a therapeutic target that inhibits metastasis. Genes Cancer 2011;2:1023-33. [PMID: 22737268 DOI: 10.1177/1947601912440878] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
33 Yeung YT, Fan S, Lu B, Yin S, Yang S, Nie W, Wang M, Zhou L, Li T, Li X, Bode AM, Dong Z. CELF2 suppresses non-small cell lung carcinoma growth by inhibiting the PREX2-PTEN interaction. Carcinogenesis 2020;41:377-89. [PMID: 31241130 DOI: 10.1093/carcin/bgz113] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
34 Lee JH, Yun CW, Lee SH. Cellular Prion Protein Enhances Drug Resistance of Colorectal Cancer Cells via Regulation of a Survival Signal Pathway. Biomol Ther (Seoul) 2018;26:313-21. [PMID: 28822989 DOI: 10.4062/biomolther.2017.033] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
35 Hamilton G. Comparison of Intracellular Stress Response of NCI-H526 Small Cell Lung Cancer (SCLC) Cells to Platinum(II) Cisplatin and Platinum(IV) Oxoplatin. Cancers (Basel) 2014;6:1487-99. [PMID: 25006835 DOI: 10.3390/cancers6031487] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
36 Osei E, Lumini J, Gunasekara D, Osei B, Asare A, Laflamme R. A review of predictive, prognostic and diagnostic biomarkers for non-small-cell lung cancer: towards personalised and targeted cancer therapy. J Radiother Pract 2020;19:370-84. [DOI: 10.1017/s1460396919000876] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Wang L, Yamaguchi S, Burstein MD, Terashima K, Chang K, Ng HK, Nakamura H, He Z, Doddapaneni H, Lewis L. Novel somatic and germline mutations in intracranial germ cell tumours. Nature. 2014;511:241-245. [PMID: 24896186 DOI: 10.1038/nature13296] [Cited by in Crossref: 116] [Cited by in F6Publishing: 87] [Article Influence: 14.5] [Reference Citation Analysis]
38 Chen M, Gu J, Delclos GL, Killary AM, Fan Z, Hildebrandt MA, Chamberlain RM, Grossman HB, Dinney CP, Wu X. Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients. Carcinogenesis 2010;31:1387-91. [PMID: 20530239 DOI: 10.1093/carcin/bgq110] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 3.8] [Reference Citation Analysis]
39 Malkomes P, Lunger I, Luetticke A, Oppermann E, Haetscher N, Serve H, Holzer K, Bechstein WO, Rieger MA. Selective AKT Inhibition by MK-2206 Represses Colorectal Cancer-Initiating Stem Cells. Ann Surg Oncol 2016;23:2849-57. [PMID: 27059026 DOI: 10.1245/s10434-016-5218-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
40 Hildebrandt MA, Yang H, Hung MC, Izzo JG, Huang M, Lin J, Ajani JA, Wu X. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol. 2009;27:857-871. [PMID: 19164214 DOI: 10.1200/jco.2008.17.6297] [Cited by in Crossref: 123] [Cited by in F6Publishing: 75] [Article Influence: 9.5] [Reference Citation Analysis]
41 Davaadelger B, Duan L, Perez RE, Gitelis S, Maki CG. Crosstalk between the IGF-1R/AKT/mTORC1 pathway and the tumor suppressors p53 and p27 determines cisplatin sensitivity and limits the effectiveness of an IGF-1R pathway inhibitor. Oncotarget 2016;7:27511-26. [PMID: 27050276 DOI: 10.18632/oncotarget.8484] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
42 Lane D, Matte I, Rancourt C, Piché A. The prosurvival activity of ascites against TRAIL is associated with a shorter disease-free interval in patients with ovarian cancer. J Ovarian Res 2010;3:1. [PMID: 20157422 DOI: 10.1186/1757-2215-3-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
43 Geng W, Ng KT, Sun CK, Yau WL, Liu XB, Cheng Q, Poon RT, Lo CM, Man K, Fan ST. The role of proline rich tyrosine kinase 2 (Pyk2) on cisplatin resistance in hepatocellular carcinoma. PLoS One 2011;6:e27362. [PMID: 22096562 DOI: 10.1371/journal.pone.0027362] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
44 Fernández de Mattos S, Villalonga P, Clardy J, Lam EW. FOXO3a mediates the cytotoxic effects of cisplatin in colon cancer cells. Mol Cancer Ther 2008;7:3237-46. [PMID: 18852127 DOI: 10.1158/1535-7163.MCT-08-0398] [Cited by in Crossref: 87] [Cited by in F6Publishing: 43] [Article Influence: 6.2] [Reference Citation Analysis]
45 Shen CY, Chen LH, Lin YF, Lai LC, Chuang EY, Tsai MH. Mitomycin C treatment induces resistance and enhanced migration via phosphorylated Akt in aggressive lung cancer cells. Oncotarget 2016;7:79995-80007. [PMID: 27833080 DOI: 10.18632/oncotarget.13237] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
46 Chen J, Shao P, Cao Q, Li P, Li J, Cai H, Zhu J, Wang M, Zhang Z, Qin C, Yin C. Genetic variations in a PTEN/AKT/mTOR axis and prostate cancer risk in a Chinese population. PLoS One 2012;7:e40817. [PMID: 22815832 DOI: 10.1371/journal.pone.0040817] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
47 Wang YL, Zhu BJ, Qi ZZ, Wang HJ, Zhou XD. Akt1 enhances CA916798 expression through mTOR pathway. PLoS One 2013;8:e62327. [PMID: 23667466 DOI: 10.1371/journal.pone.0062327] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
48 Zhang J, Zhang LL, Shen L, Xu XM, Yu HG. Regulation of AKT gene expression by cisplatin. Oncol Lett 2013;5:756-60. [PMID: 23426872 DOI: 10.3892/ol.2013.1132] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
49 Chen B, Liu Z, Zhang J, Wang H, Yu B. RNA sequencing identifies gene expression profile changes associated with β-estradiol treatment in U2OS osteosarcoma cells. Onco Targets Ther 2017;10:3421-7. [PMID: 28744146 DOI: 10.2147/OTT.S135396] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
50 Gao C, Zhuang J, Zhou C, Li H, Liu C, Liu L, Feng F, Liu R, Sun C. SNP mutation-related genes in breast cancer for monitoring and prognosis of patients: A study based on the TCGA database. Cancer Med 2019;8:2303-12. [PMID: 30883028 DOI: 10.1002/cam4.2065] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
51 Shen L, Du M, Wang C, Gu D, Wang M, Zhang Q, Zhao T, Zhang X, Tan Y, Huo X, Gong W, Xu Z, Chen J, Zhang Z. Clinical significance of POU5F1P1 rs10505477 polymorphism in Chinese gastric cancer patients receving cisplatin-based chemotherapy after surgical resection. Int J Mol Sci 2014;15:12764-77. [PMID: 25046748 DOI: 10.3390/ijms150712764] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
52 Yamamoto T, Ohno T, Wakahara K, Nagano A, Kawai G, Saitou M, Takigami I, Matsuhashi A, Yamada K, Shimizu K. Simultaneous inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways augment the sensitivity to actinomycin D in Ewing sarcoma. J Cancer Res Clin Oncol 2009;135:1125-36. [PMID: 19205734 DOI: 10.1007/s00432-009-0554-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
53 Li G, Wang X, Luo Q, Gan C. Identification of key genes and long non‑coding RNAs in celecoxib‑treated lung squamous cell carcinoma cell line by RNA‑sequencing. Mol Med Rep 2018;17:6456-64. [PMID: 29512696 DOI: 10.3892/mmr.2018.8656] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
54 Huang Y, Chuang AY, Ratovitski EA. Phospho-ΔNp63α/miR-885-3p axis in tumor cell life and cell death upon cisplatin exposure. Cell Cycle 2011;10:3938-47. [PMID: 22071691 DOI: 10.4161/cc.10.22.18107] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 5.9] [Reference Citation Analysis]
55 Bezler M, Hengstler JG, Ullrich A. Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells. Mol Oncol 2012;6:516-29. [PMID: 22841590 DOI: 10.1016/j.molonc.2012.07.001] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 4.9] [Reference Citation Analysis]
56 Ladjohounlou R, Louati S, Lauret A, Gauthier A, Ardail D, Magne N, Alphonse G, Rodriguez-Lafrasse C. Ceramide-Enriched Membrane Domains Contribute to Targeted and Nontargeted Effects of Radiation through Modulation of PI3K/AKT Signaling in HNSCC Cells. Int J Mol Sci 2020;21:E7200. [PMID: 33003449 DOI: 10.3390/ijms21197200] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
57 He Y, Sun MM, Zhang GG, Yang J, Chen KS, Xu WW, Li B. Targeting PI3K/Akt signal transduction for cancer therapy. Sig Transduct Target Ther 2021;6. [DOI: 10.1038/s41392-021-00828-5] [Reference Citation Analysis]
58 Li K, Chen B, Xu L, Feng J, Xia G, Cheng J, Wang J, Gao F, Wang X. Reversal of multidrug resistance by cisplatin-loaded magnetic Fe3O4 nanoparticles in A549/DDP lung cancer cells in vitro and in vivo. Int J Nanomedicine 2013;8:1867-77. [PMID: 23690684 DOI: 10.2147/IJN.S43752] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 0.1] [Reference Citation Analysis]
59 Chung LY, Tang SJ, Wu YC, Yang KC, Huang HJ, Sun GH, Sun KH. Platinum-based combination chemotherapy triggers cancer cell death through induction of BNIP3 and ROS, but not autophagy. J Cell Mol Med 2020;24:1993-2003. [PMID: 31856355 DOI: 10.1111/jcmm.14898] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
60 Zhang J, Wei Y, Min J, Wang Y, Yin L, Cao G, Shen H. Knockdown of RAP2A gene expression suppresses cisplatin resistance in gastric cancer cells. Oncol Lett 2020;19:350-8. [PMID: 31897147 DOI: 10.3892/ol.2019.11086] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
61 Yoon H, Kim DJ, Ahn EH, Gellert GC, Shay JW, Ahn CH, Lee YB. Antitumor activity of a novel antisense oligonucleotide against Akt1. J Cell Biochem 2009;108:832-8. [PMID: 19693774 DOI: 10.1002/jcb.22311] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
62 Liu Z, Ma L, Wen ZS, Cheng YX, Zhou GB. Ethoxysanguinarine Induces Inhibitory Effects and Downregulates CIP2A in Lung Cancer Cells. ACS Med Chem Lett 2014;5:113-8. [PMID: 24900782 DOI: 10.1021/ml400341k] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
63 Wang D, Wu X. In vitro and in vivo targeting of bladder carcinoma with metformin in combination with cisplatin. Oncol Lett 2015;10:975-81. [PMID: 26622608 DOI: 10.3892/ol.2015.3267] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
64 Pirlog R, Drula R, Nutu A, Calin GA, Berindan-Neagoe I. The Roles of the Colon Cancer Associated Transcript 2 (CCAT2) Long Non-Coding RNA in Cancer: A Comprehensive Characterization of the Tumorigenic and Molecular Functions. Int J Mol Sci 2021;22:12491. [PMID: 34830370 DOI: 10.3390/ijms222212491] [Reference Citation Analysis]
65 Hill DP, Harper A, Malcolm J, McAndrews MS, Mockus SM, Patterson SE, Reynolds T, Baker EJ, Bult CJ, Chesler EJ, Blake JA. Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance. BMC Cancer. 2019;19:1039. [PMID: 31684899 DOI: 10.1186/s12885-019-6278-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
66 Carden CP, Stewart A, Thavasu P, Kipps E, Pope L, Crespo M, Miranda S, Attard G, Garrett MD, Clarke PA, Workman P, de Bono JS, Gore M, Kaye SB, Banerji U. The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer. Mol Cancer Ther 2012;11:1609-17. [PMID: 22556379 DOI: 10.1158/1535-7163.MCT-11-0996] [Cited by in Crossref: 55] [Cited by in F6Publishing: 42] [Article Influence: 5.5] [Reference Citation Analysis]
67 Liu Z, Ma L, Wen ZS, Hu Z, Wu FQ, Li W, Liu J, Zhou GB. Cancerous inhibitor of PP2A is targeted by natural compound celastrol for degradation in non-small-cell lung cancer. Carcinogenesis 2014;35:905-14. [PMID: 24293411 DOI: 10.1093/carcin/bgt395] [Cited by in Crossref: 69] [Cited by in F6Publishing: 60] [Article Influence: 7.7] [Reference Citation Analysis]
68 Sridharan S, Basu A. S6 kinase 2 promotes breast cancer cell survival via Akt. Cancer Res. 2011;71:2590-2599. [PMID: 21427355 DOI: 10.1158/0008-5472.can-10-3253] [Cited by in Crossref: 34] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
69 Lah JJ, Cui W, Hu KQ. Effects and mechanisms of silibinin on human hepatoma cell lines. World J Gastroenterol 2007; 13(40): 5299-5305 [PMID: 17879397 DOI: 10.3748/wjg.v13.i40.5299] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 60] [Article Influence: 4.3] [Reference Citation Analysis]
70 Shao J, Li Y, Zhao P, Yue X, Jiang J, Liang X, He X. Association of mTOR polymorphisms with cancer risk and clinical outcomes: a meta-analysis. PLoS One 2014;9:e97085. [PMID: 24816861 DOI: 10.1371/journal.pone.0097085] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
71 McDonald JM, Pelloski CE, Ledoux A, Sun M, Raso G, Komaki R, Wistuba II, Bekele BN, Aldape K. Elevated phospho-S6 expression is associated with metastasis in adenocarcinoma of the lung. Clin Cancer Res 2008;14:7832-7. [PMID: 19047111 DOI: 10.1158/1078-0432.CCR-08-0565] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
72 Bach MD, Sørensen BH, Lambert IH. Stress-induced modulation of volume-regulated anions channels in human alveolar carcinoma cells. Physiol Rep 2018;6:e13869. [PMID: 30318853 DOI: 10.14814/phy2.13869] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
73 Lee HS, Lee IH, Kang K, Park SI, Kwon TW, Lee DY. Uncovering the Anti-Lung-Cancer Mechanisms of the Herbal Drug FDY2004 by Network Pharmacology. Evid Based Complement Alternat Med 2021;2021:6644018. [PMID: 33628308 DOI: 10.1155/2021/6644018] [Reference Citation Analysis]
74 Johansson D, Andersson C, Moharer J, Johansson A, Behnam-Motlagh P. Cisplatin-induced expression of Gb3 enables verotoxin-1 treatment of cisplatin resistance in malignant pleural mesothelioma cells. Br J Cancer 2010;102:383-91. [PMID: 20010943 DOI: 10.1038/sj.bjc.6605467] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
75 Avan A, Narayan R, Giovannetti E, Peters GJ. Role of Akt signaling in resistance to DNA-targeted therapy. World J Clin Oncol 2016; 7(5): 352-369 [PMID: 27777878 DOI: 10.5306/wjco.v7.i5.352] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 33] [Article Influence: 6.2] [Reference Citation Analysis]
76 Keedy VL. Treating metastatic soft-tissue or bone sarcomas - potential role of ridaforolimus. Onco Targets Ther 2012;5:153-60. [PMID: 22942649 DOI: 10.2147/OTT.S19055] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
77 Chen J, Wang L, Tang Y, Gong G, Liu L, Chen M, Chen Z, Cui Y, Li C, Cheng X, Qi L, Zu X. Maspin enhances cisplatin chemosensitivity in bladder cancer T24 and 5637 cells and correlates with prognosis of muscle-invasive bladder cancer patients receiving cisplatin based neoadjuvant chemotherapy. J Exp Clin Cancer Res. 2016;35:2. [PMID: 26733306 DOI: 10.1186/s13046-015-0282-y] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
78 Duldulao MP, Lee W, Nelson RA, Li W, Chen Z, Kim J, Garcia-Aguilar J. Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma. Ann Surg Oncol 2013;20:2166-71. [PMID: 23456389 DOI: 10.1245/s10434-013-2910-0] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 6.3] [Reference Citation Analysis]
79 Pal I, Mandal M. PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes. Acta Pharmacol Sin 2012;33:1441-58. [PMID: 22983389 DOI: 10.1038/aps.2012.72] [Cited by in Crossref: 113] [Cited by in F6Publishing: 94] [Article Influence: 11.3] [Reference Citation Analysis]
80 Yan F, Shen N, Pang J, Zhao N, Deng B, Li B, Yang Y, Yang P, Molina JR, Liu S. A regulatory circuit composed of DNA methyltransferases and receptor tyrosine kinases controls lung cancer cell aggressiveness. Oncogene 2017;36:6919-28. [PMID: 28869603 DOI: 10.1038/onc.2017.305] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
81 Dashti F, Mirazimi SMA, Rabiei N, Fathazam R, Rabiei N, Piroozmand H, Vosough M, Rahimian N, Hamblin MR, Mirzaei H. The role of non-coding RNAs in chemotherapy for gastrointestinal cancers. Mol Ther Nucleic Acids 2021;26:892-926. [PMID: 34760336 DOI: 10.1016/j.omtn.2021.10.004] [Reference Citation Analysis]
82 Molife LR, Yan L, Vitfell-Rasmussen J, Zernhelt AM, Sullivan DM, Cassier PA, Chen E, Biondo A, Tetteh E, Siu LL. Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors. J Hematol Oncol. 2014;7:1. [PMID: 24387695 DOI: 10.1186/1756-8722-7-1] [Cited by in Crossref: 88] [Cited by in F6Publishing: 75] [Article Influence: 11.0] [Reference Citation Analysis]
83 Fei HR, Chen G, Wang JM, Wang FZ. Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of Akt phosphorylation. Cytotechnology 2010;62:449-60. [PMID: 20842425 DOI: 10.1007/s10616-010-9299-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 39] [Article Influence: 2.8] [Reference Citation Analysis]
84 Carden CP, Stewart A, Thavasu P, Kipps E, Pope L, Crespo M, Miranda S, Attard G, Garrett MD, Clarke PA, Workman P, de Bono JS, Gore M, Kaye SB, Banerji U. The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer. Mol Cancer Ther 2012;11:1609-17. [PMID: 22556379 DOI: 10.1158/1535-7163.MCT-11-0996] [Reference Citation Analysis]
85 Lu X, Liu M, Liao Y, Huang C, Chai L, Jin Y, Xiong Q, Chen B. Meta-analysis of the association between mTORC1-related genes polymorphisms and cancer risk. Pathol Res Pract 2021;229:153696. [PMID: 34839094 DOI: 10.1016/j.prp.2021.153696] [Reference Citation Analysis]
86 Yan F, Pang J, Peng Y, Molina JR, Yang P, Liu S. Elevated Cellular PD1/PD-L1 Expression Confers Acquired Resistance to Cisplatin in Small Cell Lung Cancer Cells. PLoS One 2016;11:e0162925. [PMID: 27610620 DOI: 10.1371/journal.pone.0162925] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 6.2] [Reference Citation Analysis]
87 Huang T, Cheng X, Chahoud J, Sarhan A, Tamboli P, Rao P, Guo M, Manyam G, Zhang L, Xiang Y, Han L, Shang X, Deng P, Luo Y, Lu X, Feng S, Ferrer MM, Alan Wang Y, DePinho RA, Pettaway CA, Lu X. Effective combinatorial immunotherapy for penile squamous cell carcinoma. Nat Commun 2020;11:2124. [PMID: 32358507 DOI: 10.1038/s41467-020-15980-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
88 Liang SQ, Bührer ED, Berezowska S, Marti TM, Xu D, Froment L, Yang H, Hall SRR, Vassella E, Yang Z, Kocher GJ, Amrein MA, Riether C, Ochsenbein AF, Schmid RA, Peng RW. mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer. Oncogene 2019;38:622-36. [PMID: 30171261 DOI: 10.1038/s41388-018-0479-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
89 Kim HK, Choi IJ, Kim CG, Kim HS, Oshima A, Michalowski A, Green JE. A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients. PLoS One. 2011;6:e16694. [PMID: 21364753 DOI: 10.1371/journal.pone.0016694] [Cited by in Crossref: 72] [Cited by in F6Publishing: 67] [Article Influence: 6.5] [Reference Citation Analysis]
90 Ito Y, Narita N, Nomi N, Sugimoto C, Takabayashi T, Yamada T, Karaya K, Matsumoto H, Fujieda S. Suppression of Poly(rC)-Binding Protein 4 (PCBP4) reduced cisplatin resistance in human maxillary cancer cells. Sci Rep 2015;5:12360. [PMID: 26196957 DOI: 10.1038/srep12360] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
91 Eckstein N, Servan K, Girard L, Cai D, von Jonquieres G, Jaehde U, Kassack MU, Gazdar AF, Minna JD, Royer HD. Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells. J Biol Chem 2008;283:739-50. [PMID: 17942395 DOI: 10.1074/jbc.M706287200] [Cited by in Crossref: 73] [Cited by in F6Publishing: 41] [Article Influence: 4.9] [Reference Citation Analysis]
92 Szymczyk J, Sluzalska KD, Materla I, Opalinski L, Otlewski J, Zakrzewska M. FGF/FGFR-Dependent Molecular Mechanisms Underlying Anti-Cancer Drug Resistance. Cancers (Basel) 2021;13:5796. [PMID: 34830951 DOI: 10.3390/cancers13225796] [Reference Citation Analysis]
93 Zhu B, Zhou X. [The study of PI3K/AKT pathway in lung cancer metastasis and drug resistance]. Zhongguo Fei Ai Za Zhi 2011;14:689-94. [PMID: 21859552 DOI: 10.3779/j.issn.1009-3419.2011.08.10] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
94 Sun D, Wang J, Zhang H, Liu S, Wei P, Wang H, Xu Z, Fu Q, Zhang K. MK2206 Enhances Cisplatin-Induced Cytotoxicity and Apoptosis in Testicular Cancer Through Akt Signaling Pathway Inhibition. Transl Oncol 2020;13:100769. [PMID: 32422572 DOI: 10.1016/j.tranon.2020.100769] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
95 Zhu BS, Yu LY, Zhao K, Wu YY, Cheng XL, Wu Y, Zhong FY, Gong W, Chen Q, Xing CG. Effects of small interfering RNA inhibit Class I phosphoinositide 3-kinase on human gastric cancer cells. World J Gastroenterol 2013; 19(11): 1760-1769 [PMID: 23555164 DOI: 10.3748/wjg.v19.i11.1760] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]